Trifluoperazine

Generic Name: Trifluoperazine
Brand Name: TRIFLUZIC®
Dosage Form: Injection 1mg/1ml
Pharmacological Category: Phenothiazines
Therapeutic Category: Antipsychotic drugs
Pregnancy Category: Category C

Pharmacology

Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Pharmacokinetics:

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

Indications:

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

Contraindications:

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

Precautions:

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

Drug Interactions:

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

Side Effects:

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

Storage:

• Store below 30 C°
• Protect from light and freezing

Packing:

• Injection 1mg/1ml: Box of 10 Ampoules

stdClass Object ( [nid] => 269 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373630958 [changed] => 1388743023 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 114 [translate] => 0 [vid] => 269 [revision_uid] => 1 [title] => Trifluoperazine [body] =>
Image: 
Brand Name: 

TRIFLUZIC®

Dosage Form: 

Injection 1mg/1ml

Pharmacological Category: 

Phenothiazines

Therapeutic Category: 

Antipsychotic drugs

Pregnancy Category: 

Category C

Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Pharmacokinetics: 

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

Indications: 

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

Contraindications: 

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

Precautions: 

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

Drug Interactions: 

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

Side Effects: 

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Injection 1mg/1ml: Box of 10 Ampoules

[log] => [revision_timestamp] => 1388743023 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-aTcSqa5gxC3qlJ6qWYJHsxgkPEq9KwPBBC-KEX1q3PQ";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/trifluoperazine [field_one_image] => Array ( [0] => Array ( [fid] => 190 [uid] => 1 [filename] => trifluoperazine_s.jpg [filepath] => sites/default/files/images/trifluoperazine_s.jpg [filemime] => image/jpeg [filesize] => 55401 [status] => 1 [timestamp] => 1329490556 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 269 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => TRIFLUZIC® [format] => 1 [safe] =>

TRIFLUZIC®

[view] =>

TRIFLUZIC®

) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates) • Bone marrow depression or blood dyscrasias. • Liver damage. • Known hypersensitivity to phenothiazines. [format] => 1 [safe] =>

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

[view] =>

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 1mg/1ml [format] => 1 [safe] =>

Injection 1mg/1ml

[view] =>

Injection 1mg/1ml

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => • atropine • lithium • phenytoin (Dilantin); • an antibiotic; • birth control pills or hormone replacement estrogens; • a blood thinner such as warfarin (Coumadin); • certain asthma medications or bronchodilators; • a diuretic (water pill); • drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax); • incontinence medications; • insulin or diabetes medications you take by mouth; • medication for nausea, vomiting, or motion sickness; • medications to treat or prevent malaria; • medications used for general anesthesia; • medicines used to prevent organ transplant rejection; • numbing medicine such as lidocaine or Novocain; • a stimulant or ADHD medication; • ulcer or irritable bowel medications; or • medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma). [format] => 1 [safe] =>

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

[view] =>

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

) ) [field_indications] => Array ( [0] => Array ( [value] => trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). [format] => 1 [safe] =>

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

[view] =>

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

) ) [field_packing] => Array ( [0] => Array ( [value] => • Injection 1mg/1ml: Box of 10 Ampoules [format] => 1 [safe] =>

• Injection 1mg/1ml: Box of 10 Ampoules

[view] =>

• Injection 1mg/1ml: Box of 10 Ampoules

) ) [field_pdf] => Array ( [0] => Array ( [fid] => 191 [uid] => 1 [filename] => trifluoperazine.pdf [filepath] => sites/default/files/pdf/trifluoperazine.pdf [filemime] => application/pdf [filesize] => 141590 [status] => 1 [timestamp] => 1329490812 [list] => 1 [data] => [i18nsync] => 1 [nid] => 269 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => Absorption: Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration. Distribution: Highly bound to plasma proteins and distributed into breast milk. Metabolism: The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative. Elimination: Terminal half-life is approximately 22 h. [format] => 1 [safe] =>

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

[view] =>

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Phenothiazines [format] => 1 [safe] =>

Phenothiazines

[view] =>

Phenothiazines

) ) [field_precautions] => Array ( [0] => Array ( [value] => Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy. Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn. Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure. Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes. An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome. With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics. Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat. As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma. Phenothiazines may diminish the effect of oral anticoagulants. Phenothiazines can produce alpha-adrenergic blockade. Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs. Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity. Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque. The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results. [format] => 1 [safe] =>

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

[view] =>

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => Category C [format] => 1 [safe] =>

Category C

[view] =>

Category C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => • twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs; • tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking; • feeling restless, jittery, or agitated; • very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out; • decreased night vision, tunnel vision, watery eyes, increased sensitivity to light; • seizure (black-out or convulsions); • nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes); • urinating less than usual or not at all; • pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms; • joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or • slow heart rate, weak pulse, fainting, slow breathing (breathing may stop). Less serious side effects may include: • dizziness, drowsiness, anxiety, sleep problems (insomnia); • blurred vision, headache; • dry mouth, stuffy nose; • constipation; • breast swelling or discharge; • missed menstrual periods; • weight gain, swelling in your hands or feet; or • impotence, trouble having an orgasm. [format] => 1 [safe] =>

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

[view] =>

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[view] =>

• Store below 30 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Antipsychotic drugs [format] => 1 [safe] =>

Antipsychotic drugs

[view] =>

Antipsychotic drugs

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [4] => stdClass Object ( [tid] => 4 [vid] => 1 [name] => Antiparkinson Drugs, Antidepressants,Antiepileptics, Anxiolytic Sedative, Hypnotics and Antipsychotics [description] => [weight] => 2 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 190 [uid] => 1 [filename] => trifluoperazine_s.jpg [filepath] => sites/default/files/images/trifluoperazine_s.jpg [filemime] => image/jpeg [filesize] => 55401 [status] => 1 [timestamp] => 1329490556 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 269 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
[#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => TRIFLUZIC® [format] => 1 [safe] =>

TRIFLUZIC®

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

TRIFLUZIC®

) [#title] => [#description] => [#children] =>

TRIFLUZIC®

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

TRIFLUZIC®

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Brand Name: 

TRIFLUZIC®

[#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Injection 1mg/1ml [format] => 1 [safe] =>

Injection 1mg/1ml

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Injection 1mg/1ml

) [#title] => [#description] => [#children] =>

Injection 1mg/1ml

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Injection 1mg/1ml

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Dosage Form: 

Injection 1mg/1ml

[#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Phenothiazines [format] => 1 [safe] =>

Phenothiazines

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Phenothiazines

) [#title] => [#description] => [#children] =>

Phenothiazines

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Phenothiazines

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacological Category: 

Phenothiazines

[#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Antipsychotic drugs [format] => 1 [safe] =>

Antipsychotic drugs

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Antipsychotic drugs

) [#title] => [#description] => [#children] =>

Antipsychotic drugs

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Antipsychotic drugs

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Therapeutic Category: 

Antipsychotic drugs

[#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Category C [format] => 1 [safe] =>

Category C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Category C

) [#title] => [#description] => [#children] =>

Category C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Category C

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pregnancy Category: 

Category C

[#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Absorption: Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration. Distribution: Highly bound to plasma proteins and distributed into breast milk. Metabolism: The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative. Elimination: Terminal half-life is approximately 22 h. [format] => 1 [safe] =>

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

) [#title] => [#description] => [#children] =>

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Pharmacokinetics: 

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

[#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). [format] => 1 [safe] =>

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

) [#title] => [#description] => [#children] =>

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Indications: 

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

[#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates) • Bone marrow depression or blood dyscrasias. • Liver damage. • Known hypersensitivity to phenothiazines. [format] => 1 [safe] =>

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

) [#title] => [#description] => [#children] =>

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Contraindications: 

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

[#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy. Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn. Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure. Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes. An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome. With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind. Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics. Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat. As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma. Phenothiazines may diminish the effect of oral anticoagulants. Phenothiazines can produce alpha-adrenergic blockade. Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs. Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity. Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque. The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results. [format] => 1 [safe] =>

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

) [#title] => [#description] => [#children] =>

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Precautions: 

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

[#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • atropine • lithium • phenytoin (Dilantin); • an antibiotic; • birth control pills or hormone replacement estrogens; • a blood thinner such as warfarin (Coumadin); • certain asthma medications or bronchodilators; • a diuretic (water pill); • drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax); • incontinence medications; • insulin or diabetes medications you take by mouth; • medication for nausea, vomiting, or motion sickness; • medications to treat or prevent malaria; • medications used for general anesthesia; • medicines used to prevent organ transplant rejection; • numbing medicine such as lidocaine or Novocain; • a stimulant or ADHD medication; • ulcer or irritable bowel medications; or • medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma). [format] => 1 [safe] =>

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

) [#title] => [#description] => [#children] =>

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Drug Interactions: 

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

[#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs; • tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking; • feeling restless, jittery, or agitated; • very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out; • decreased night vision, tunnel vision, watery eyes, increased sensitivity to light; • seizure (black-out or convulsions); • nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes); • urinating less than usual or not at all; • pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms; • joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or • slow heart rate, weak pulse, fainting, slow breathing (breathing may stop). Less serious side effects may include: • dizziness, drowsiness, anxiety, sleep problems (insomnia); • blurred vision, headache; • dry mouth, stuffy nose; • constipation; • breast swelling or discharge; • missed menstrual periods; • weight gain, swelling in your hands or feet; or • impotence, trouble having an orgasm. [format] => 1 [safe] =>

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

) [#title] => [#description] => [#children] =>

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Side Effects: 

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

[#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Storage: 

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Injection 1mg/1ml: Box of 10 Ampoules [format] => 1 [safe] =>

• Injection 1mg/1ml: Box of 10 Ampoules

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Injection 1mg/1ml: Box of 10 Ampoules

) [#title] => [#description] => [#children] =>

• Injection 1mg/1ml: Box of 10 Ampoules

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Injection 1mg/1ml: Box of 10 Ampoules

[#printed] => 1 ) [#title] => [#description] => [#children] =>
Packing: 

• Injection 1mg/1ml: Box of 10 Ampoules

[#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [fid] => 191 [uid] => 1 [filename] => trifluoperazine.pdf [filepath] => sites/default/files/pdf/trifluoperazine.pdf [filemime] => application/pdf [filesize] => 141590 [status] => 1 [timestamp] => 1329490812 [list] => 1 [data] => [i18nsync] => 1 [nid] => 269 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>
Image: 
Brand Name: 

TRIFLUZIC®

Dosage Form: 

Injection 1mg/1ml

Pharmacological Category: 

Phenothiazines

Therapeutic Category: 

Antipsychotic drugs

Pregnancy Category: 

Category C

Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Pharmacokinetics: 

Absorption:
Readily absorbed from the GI tract. T max occurs 1.5 to 6 h after oral administration.

Distribution:
Highly bound to plasma proteins and distributed into breast milk.

Metabolism:
The major metabolite is the possibly active N-oxide; other metabolites are the sulfoxide and the 7-hydroxy derivative.

Elimination:
Terminal half-life is approximately 22 h.

Indications: 

trifluoperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).

Contraindications: 

• Comatose states or in the presence of large amounts of CNS depressants (e.g., alcohol, barbiturates, opiates)
• Bone marrow depression or blood dyscrasias.
• Liver damage.
• Known hypersensitivity to phenothiazines.

Precautions: 

Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Thrombocytopenia and anemia have been reported in patients receiving the drug. Agranulocytosis and pancytopenia have also been reported—warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate cellular depression, stop treatment and start antibiotic and other suitable therapy.

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment.

One result of therapy may be an increase in mental and physical activity. For example, a few patients with angina pectoris have complained of increased pain while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn.
Because hypotension has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of hypotension after injection, keep patient lying down and observe for at least 2 hours. If hypotension occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, Norepinephrine and Phenylephrine are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

Since certain phenothiazines have been reported to produce retinopathy, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes.

An antiemetic action of trifluoperazine may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome.
With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.

Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.

As with all drugs which exert an anticholinergic effect, and/or cause mydriasis, trifluoperazine should be used with caution in patients with glaucoma.

Phenothiazines may diminish the effect of oral anticoagulants.

Phenothiazines can produce alpha-adrenergic blockade.

Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently.

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.

Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of Phenytoin and thus precipitate Phenytoin toxicity.

Drugs which lower the seizure threshold, including phenothiazine derivatives, should not be used with Metrizamide. As with other phenothiazine derivatives,trifluoperazine should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours postprocedure and should not be used for the control of nausea and vomiting occurring either prior to myelography or postprocedure with Amipaque.
The presence of phenothiazines may produce false-positive phenylketonuria (PKU) test results.

Drug Interactions: 

• atropine
• lithium
• phenytoin (Dilantin);
• an antibiotic;
• birth control pills or hormone replacement estrogens;
• a blood thinner such as warfarin (Coumadin);
• certain asthma medications or bronchodilators;
• a diuretic (water pill);
• drugs to treat high blood pressure or a prostate disorder, such as alfuzosin ,doxazosin prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);
• incontinence medications;
• insulin or diabetes medications you take by mouth;
• medication for nausea, vomiting, or motion sickness;
• medications to treat or prevent malaria;
• medications used for general anesthesia;
• medicines used to prevent organ transplant rejection;
• numbing medicine such as lidocaine or Novocain;
• a stimulant or ADHD medication;
• ulcer or irritable bowel medications; or
• medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).

Side Effects: 

• twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
• tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;
• feeling restless, jittery, or agitated;
• very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;
• decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;
• seizure (black-out or convulsions);
• nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);
• urinating less than usual or not at all;
• pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;
• joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or
• slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious side effects may include:

• dizziness, drowsiness, anxiety, sleep problems (insomnia);
• blurred vision, headache;
• dry mouth, stuffy nose;
• constipation;
• breast swelling or discharge;
• missed menstrual periods;
• weight gain, swelling in your hands or feet; or
• impotence, trouble having an orgasm.

Storage: 

• Store below 30 C°
• Protect from light and freezing

Packing: 

• Injection 1mg/1ml: Box of 10 Ampoules

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/114 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => تری فلوئوپرازین [class] => translation-link ) ) ) )
button

CONTACT US:

Head Office:
Address: No.1, Beastoon Ave., Dr. Fatemi Sq., Tehran1431663135 Iran
Tel: (+98 21)-889 65323
Fax: (+98 21)-889 57056
Factory:
Address: Caspian tamin Pharmaceutical Co., Entrance 1, Rasht Industrial Zone, Rasht, Guilan, Iran
Tel: (+98 131) 338-2511- 8
Fax: (+98 131) 338 – 2517